Most interestingly, we also saw lipid droplet accumulation in the PD mouse midbrain and in macrophages from PD patients — pointing to shared lipid stress across tissues. Peripheral lipidomics offers a window into brain pathology and could guide lipid-based biomarkers & therapeutic strategies for PD

🔑 Key findings:

1. Peripheral lipidomic signatures reflect CNS pathology
2. Conserved dysregulation in sphingolipids, glycerophospholipids, and fatty acids
3. Elevated triacylglycerols & monoacylglycerols linked to lipid droplet biogenesis

We tackled this long-standing question using a cross-species lipidomics approach. We modeled PD in mice using α-synuclein fibril injections and analyzed lipid profiles from the midbrain and plasma, then validated findings in PD patient plasma.

What a perfect capture of Sunday morning.

Looking forward to hearing about your work, Janine. See you soon.

Proud of all the lab members who worked hard on this project. Also grateful to all the collaborators and funding agencies for their support for this work. I look forward to your feedback and discussions.

Chronic administration of PD180970 (c-Abl inhibitor):
✅ Rescued DA neurons from degeneration.
✅ Reduced p-syn accumulation in the substantia nigra.
✅ Significantly suppressed neuroinflammation.

✅ Progressive loss of dopaminergic (DA) neurons & striatal projections over 24 weeks.
✅ Time-dependent p-syn accumulation in the substantia nigra, spreading to striatum & cortex.
✅ Contralateral spread of α-synuclein pathology.
✅ Activation of astrocytes and microglia

Appreciate your kind words Abhilasha. Yes, the quality of science and talks was really amazing.

Thanks for sharing Shruti. Sounds like a good idea.

Hi, I use mouse models to study Parkinson's disease. Please add me.

Same here Marie. Looking forward to a thriving community here.

Does this count sites.google.com/view/thakurl...